DSpace Repository

Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing "where" by "what"…

Show simple item record

dc.contributor.author Allegri, Ricardo Francisco
dc.date.accessioned 2021-03-02T12:51:57Z
dc.date.available 2021-03-02T12:51:57Z
dc.date.issued 2020-07
dc.identifier.citation Allegri, R F, 2020. Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing “where” by “what”…. Dement Neuropsychol 14, 237–242. https://doi.org/10.1590/1980-57642020dn14-030005 en_US
dc.identifier.uri http://localhost:8080/xmlui/handle/123456789/370
dc.identifier.uri http://www.scielo.br/pdf/dn/v14n3/1980-5764-dn-14-03-237.pdf
dc.description.abstract Neurodegenerative dementias have been described based on their phenotype, in relation to selective degeneration occurring in a particular neuroanatomical system. More recently however, the term proteinopathy has been introduced to describe diseases in which one or more altered proteins can be detected. Neurodegenerative diseases can be produced by more than one abnormal protein and each proteinopathy can determine different clinical phenotypes. Specific biomarkers have now been linked to certain molecular pathologies in live patients. In 2016, a new biomarker-based classification, currently only approved for research in Alzheimer's disease, was introduced. It is based on the evaluation three biomarkers: amyloid (A) detected on amyloid-PET or amyloid- beta 42 assay in CSF; tau (T) measured in CSF as phosphorylated tau or on tau PET imaging; and neuronal injury/neurodegeneration (N), detected by total T-tau in CSF, FDG PET hypometabolism and on MRI brain scan. Results of clinical research using the ATN biomarkers at FLENI, a Neurological Institute in Buenos Aires, Argentina have, since 2011, contributed to ongoing efforts to move away from the concept of neurodegenerative dementias and more towards one of cognitive proteinopathies. Today, clinical diagnosis in dementia can only tell us "where" abnormal tissue is found but not "what" molecular mechanisms are involved. en_US
dc.language.iso eng en_US
dc.publisher Associação Neurologia Cognitiva e do Comportamento en_US
dc.rights info:eu-repo/semantics/openAccess
dc.rights.uri https://creativecommons.org/licenses/by/2.5/ar/
dc.subject Alzheimer Disease en_US
dc.subject Enfermedad de Alzheimer en_US
dc.subject Dementia en_US
dc.subject Demencia en_US
dc.title Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing "where" by "what"… en_US
dc.type info:eu-repo/semantics/publishedVersion
dc.type info:eu-repo/semantics/article en_US
dc.description.fil Fil: Allegri, Ricardo Francisco. Fleni. Departamento de Neurología. Servicio de Neurología Cognitiva, Neuropsicología y Neuropsiquiatría; Argentina.
dc.relation.ispartofVOLUME 14
dc.relation.ispartofNUMBER 3
dc.relation.ispartofPAGINATION 237-242
dc.relation.ispartofCOUNTRY Brasil
dc.relation.ispartofCITY San Pablo
dc.relation.ispartofTITLE Dementia & neuropsychologia
dc.relation.ispartofISSN 1980-5764
dc.type.snrd info:ar-repo/semantics/artículo es_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/openAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess

Search DSpace


Browse

My Account

Statistics